115 related articles for article (PubMed ID: 38329819)
21. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
Pan X; Chen Y; Shen Y; Tantai J
Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
[TBL] [Abstract][Full Text] [Related]
24. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.
Li JM; Yang F; Li J; Yuan WQ; Wang H; Luo YQ
Med Sci Monit; 2020 Aug; 26():e925298. PubMed ID: 32764530
[TBL] [Abstract][Full Text] [Related]
25. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
Wang W; Dong ML; Zhang W; Liu T
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
[TBL] [Abstract][Full Text] [Related]
26. Cx43 reverses the resistance of A549 lung adenocarcinoma cells to cisplatin by inhibiting EMT.
Yu M; Zhang C; Li L; Dong S; Zhang N; Tong X
Oncol Rep; 2014 Jun; 31(6):2751-8. PubMed ID: 24789679
[TBL] [Abstract][Full Text] [Related]
27. ACE2 overexpression inhibits acquired platinum resistance-induced tumor angiogenesis in NSCLC.
Cheng Q; Zhou L; Zhou J; Wan H; Li Q; Feng Y
Oncol Rep; 2016 Sep; 36(3):1403-10. PubMed ID: 27460845
[TBL] [Abstract][Full Text] [Related]
28. Human RECQL5 promotes metastasis and resistance to cisplatin in non-small cell lung cancer.
Xia HW; Zhang ZQ; Yuan J; Niu QL
Life Sci; 2021 Jan; 265():118768. PubMed ID: 33217443
[TBL] [Abstract][Full Text] [Related]
29. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
30. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
31. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
32. Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a.
Chen Y; Song W; Gao Y; Dong X; Ji X
Tohoku J Exp Med; 2022 May; 257(1):33-43. PubMed ID: 35354691
[TBL] [Abstract][Full Text] [Related]
33. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
34. The CD44high Subpopulation of Multifraction Irradiation-Surviving NSCLC Cells Exhibits Partial EMT-Program Activation and DNA Damage Response Depending on Their p53 Status.
Pustovalova M; Alhaddad L; Blokhina T; Smetanina N; Chigasova A; Chuprov-Netochin R; Eremin P; Gilmutdinova I; Osipov AN; Leonov S
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673439
[TBL] [Abstract][Full Text] [Related]
35. Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer.
Zhang W; Wan M; Ma L; Liu X; He J
Cell Biol Int; 2013 Jan; 37(1):47-53. PubMed ID: 23319321
[TBL] [Abstract][Full Text] [Related]
36. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
37. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
Farhan M; Malik A; Ullah MF; Afaq S; Faisal M; Farooqi AA; Biersack B; Schobert R; Ahmad A
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781783
[TBL] [Abstract][Full Text] [Related]
38. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Tian FM; Zhong CY; Wang XN; Meng Y
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
[TBL] [Abstract][Full Text] [Related]
39. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
40. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]